Reductions in eosinophil biomarkers by benralizumab in patients with asthma

Respiratory Medicine

Volumn 111, Issue , 2016, Pages 21-29

  Pham, Tuyet Hang ^a   Damera, Gautam ^a   Newbold, Paul ^a   Ranade, Koustubh ^a  

^a MEDIMMUNE   (United States)

Author keywords

Asthma; Benralizumab; Biomarker; Eosinophil; IL 5

Indexed keywords

ARTICLE; ASTHMA; PRIORITY JOURNAL; ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; EOSINOPHIL; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

BENRALIZUMAB; BIOLOGICAL MARKER; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHIL PROTEIN X; INTERLEUKIN 5; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ASTHMA; BIOMARKERS; DOUBLE-BLIND METHOD; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHIL-DERIVED NEUROTOXIN; EOSINOPHILS; FEMALE; HUMANS; INTERLEUKIN-5; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84959475061     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2016.01.003     Document Type: Article

References (38)

1. G. Garcia, C. Taille, P. Laveneziana, A. Bourdin, P. Chanez, and M. Humbert Anti-interleukin-5 therapy in severe asthma Eur. Respir. Rev. 22 2013 251 257
2. D.I. Blyth, T.F. Wharton, M.S. Pedrick, T.J. Savage, and S. Sanjar Airway subepithelial fibrosis in a murine model of atopic asthma: suppression by dexamethasone or anti-interleukin-5 antibody Am. J. Respir. Cell Mol. Biol. 23 2000 241 246
3. A. Trifilieff, Y. Fujitani, A.J. Coyle, M. Kopf, and C. Bertrand IL-5 deficiency abolishes aspects of airway remodelling in a murine model of lung inflammation Clin. Exp. Allergy 31 2001 934 942
4. A.A. Humbles, C.M. Lloyd, S.J. McMillan, D.S. Friend, G. Xanthou, E.E. McKenna, and et al. A critical role for eosinophils in allergic airways remodeling Science 305 2004 1776 1779
5. A.B. Kay, S. Phipps, and D.S. Robinson A role for eosinophils in airway remodelling in asthma Trends Immunol. 25 2004 477 482
6. H. Tanaka, M. Komai, K. Nagao, M. Ishizaki, D. Kajiwara, K. Takatsu, and et al. Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice Am. J. Respir. Cell Mol. Biol. 31 2004 62 68
7. S.J. Wilson, H.M. Rigden, J.A. Ward, M. Laviolette, N.N. Jarjour, and R. Djukanovic The relationship between eosinophilia and airway remodelling in mild asthma Clin. Exp. Allergy 43 2013 1342 1350
8. C. Buttner, A. Lun, T. Splettstoesser, G. Kunkel, and H. Renz Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions Eur. Respir. J. 21 2003 799 803
9. P. Haldar, C.E. Brightling, B. Hargadon, S. Gupta, W. Monteiro, A. Sousa, and et al. Mepolizumab and exacerbations of refractory eosinophilic asthma N. Engl. J. Med. 360 2009 973 984
10. W.W. Busse, R. Katial, D. Gossage, S. Sari, B. Wang, R. Kolbeck, and et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma J. Allergy Clin. Immunol. 125 2010 1237 1244
11. B.S. Bochner, and G.J. Gleich What targeting eosinophils has taught us about their role in diseases J. Allergy Clin. Immunol. 126 2010 16 25
12. P.C. Fulkerson, and M.E. Rothenberg Targeting eosinophils in allergy, inflammation and beyond Nat. Rev. Drug Discov. 12 2013 117 129
13. G.J. Gleich, A.D. Klion, J.J. Lee, and P.F. Weller The consequences of not having eosinophils Allergy 68 2013 829 835
14. S.P. Hogan, H.F. Rosenberg, R. Moqbel, S. Phipps, P.S. Foster, P. Lacy, and et al. Eosinophils: biological properties and role in health and disease Clin. Exp. Allergy 38 2008 709 750
15. N.A. Molfino, D. Gossage, R. Kolbeck, J.M. Parker, and G.P. Geba Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor Clin. Exp. Allergy 42 2012 712 737
16. P.T. Flood-Page, A.N. Menzies-Gow, A.B. Kay, and D.S. Robinson Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway Am. J. Respir. Crit. Care Med. 167 2003 199 204
17. H.G. Ortega, M.C. Liu, I.D. Pavord, G.G. Brusselle, M. Fitzgerald, A. Chetta, and et al. Mepolizumab treatment in patients with severe eosinophilic asthma N. Engl. J. Med. 37 2014 1198 1207
18. M. Castro, J. Zangrilli, M.E. Wechsler, E.D. Bateman, G.G. Brusselle, P. Bardin, and et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomized, placebo-controlled, phase 3 trials Lancet Respir. Med. 3 2015 355 366
19. R. Kolbeck, A. Kozhich, M. Koike, L. Peng, C.K. Andersson, M.M. Damschroder, and et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function J. Allergy Clin. Immunol. 125 2010 1344 1353
20. M. Castro, S.E. Wenzel, E.R. Bleecker, E. Pizzichini, P. Kuna, W.W. Busse, and et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study Lancet Respir. Med. 2 2014 879 890
21. M. Laviolette, D.L. Gossage, G. Gauvreau, R. Leigh, R. Olivenstein, R. Katial, and et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia J. Allergy Clin. Immunol. 132 2013 1086 1096
22. C. Blanchard, and M.E. Rothenberg Biology of the eosinophil Adv. Immunol. 101 2009 81 121
23. J.S. Erjefalt, and C.G. Persson New aspects of degranulation and fates of airway mucosal eosinophils Am. J. Respir. Crit. Care Med. 161 2000 2074 2085
24. B. Geering, C. Stoeckle, S. Conus, and H.U. Simon Living and dying for inflammation: neutrophils, eosinophils, basophils Trends Immunol. 34 2013 398 409
25. C. Persson Primary lysis/necrosis of eosinophils and clinical control of asthma Thorax 68 2013 295
26. C. Persson, and L. Uller Primary lysis of eosinophils as a major mode of activation of eosinophils in human diseased tissues Nat. Rev. Immunol. 13 2013 902
27. A.J. Coyle, S.J. Ackerman, R. Burch, D. Proud, and C.G. Irvin Human eosinophil-granule major basic protein and synthetic polycations induce airway hyperresponsiveness in vivo dependent on bradykinin generation J. Clin. Invest. 95 1995 1735 1740
28. G.M. Walsh Eosinophil granule proteins and their role in disease Curr. Opin. Hematol. 8 2001 28 33
29. D.A. Plager, M.D. Davis, A.G. Andrews, M.J. Coenen, T.J. George, G.J. Gleich, and et al. Eosinophil ribonucleases and their cutaneous lesion-forming activity J. Immunol. 183 2009 4013 4020
30. L. O'Bryan, P. Pinkston, V. Kumaraswami, V. Vijayan, G. Yenokida, H.F. Rosenberg, and et al. Localized eosinophil degranulation mediates disease in tropical pulmonary eosinophilia Infect. Immun. 71 2003 1337 1342
31. K. Solarewicz-Madejek, T.M. Basinski, R. Crameri, M. Akdis, A. Akkaya, K. Blaser, and et al. T cells and eosinophils in bronchial smooth muscle cell death in asthma Clin. Exp. Allergy 39 2009 845 855
32. S. Cianchetti, E. Bacci, L. Ruocco, T. Pavia, M.L. Bartoli, C. Cardini, and et al. Are sputum eosinophil cationic protein and eosinophils differently associated with clinical and functional findings of asthma? Clin. Exp. Allergy 44 2014 673 680
33. D.H. Broide, G.J. Gleich, A.J. Cuomo, D.A. Coburn, E.C. Federman, L.B. Schwartz, and et al. Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway J. Allergy Clin. Immunol. 88 1991 637 648
34. M.E. Rothenberg, A.D. Klion, F.E. Roufosse, J.E. Kahn, P.F. Weller, H.-U. Simon, and et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab N. Engl. J. Med. 358 2008 1215 1228
35. J.M. Swartz, K.D. Dyer, A.W. Cheever, T. Ramalingam, L. Pesnicak, J.B. Domachowske, and et al. Schistosoma mansoni infection in eosinophil lineage-ablated mice Blood 108 2006 2420 2427
36. M.L. Stein, J.M. Villanueva, B.K. Buckmeier, Y. Yamada, A.H. Filipovich, A.H. Assa'ad, and et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels J. Allergy Clin. Immunol. 121 2008 1473 1483
37. F. Lavie, C. Miceli-Richard, M. Ittah, J. Sellam, J.E. Gottenberg, and X. Mariette Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production Ann. Rheum. Dis. 66 2007 700 703
38. A. Ghazi, A. Trikha, and W.J. Calhoun Benralizumab - a humanized mAb to IL-5R alpha with enhanced antibody-dependent cell-mediated cytotoxicity - a novel approach for the treatment of asthma Expert Opin. Biol. Ther. 12 2012 113 118